Acta Haematol
- PAN L, Zheng Y, Zheng H
Long Non-coding RNA RP11-252C15.1 is a Potential Biomarker of Prognosis and
Hallmark for Leukemogenesis in Children with B-cell Precursor Acute Lymphoblastic
Leukemia.
Acta Haematol. 2024 Mar 25. doi: 10.1159/000535461.
- CARLSON KS, Cunningham A, Stahl M, Winer E, et al
Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia
Classification Systems?
Acta Haematol. 2024;147:122-132.
- JIMENEZ-CHILLON C, Dillon R, Russell N
Optimal Post-Remission Consolidation Therapy in Patients with AML.
Acta Haematol. 2024;147:147-158.
- BUCHRITS S, Wolach O
Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.
Acta Haematol. 2024;147:159-174.
Am J Hematol
- HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia
chromosome variants do not adversely affect the achievement of treatment-free
remission in chronic myeloid leukemia.
Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.
Ann Hematol
- CHEN Y, Pan M, Chen L, Peng M, et al
Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute
promyelocytic leukemia.
Ann Hematol. 2024 Mar 27. doi: 10.1007/s00277-024-05675.
- WU CY, Yeh CM, Tsai CK, Liu CJ, et al
The influence of hospital volume and physician volume on early mortality in acute
promyelocytic leukemia patients.
Ann Hematol. 2024 Mar 26. doi: 10.1007/s00277-024-05616.
- CAI X, Liu Y, Li H, Que Y, et al
XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute
myeloid leukemia via downregulating glutathione pathway.
Ann Hematol. 2024 Mar 23. doi: 10.1007/s00277-024-05706.
Blood
- INESS AN, Bachireddy P
GPR56 in GVL: marker or mechanism?
Blood. 2024;143:1206-1207.
- MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
The remission status of AML patients after allo-HCT is associated with a distinct
single-cell bone marrow T-cell signature.
Blood. 2024;143:1269-1281.
- XIE J, Bao X, Xue SL, Shen H, et al
Venetoclax with decitabine as frontline treatment in younger adults with newly
diagnosed ELN adverse-risk AML.
Blood. 2023;142:1323-1327.
Exp Hematol
- GOSWAMI M, Bose PD
Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based
Perspective.
Exp Hematol. 2024 Mar 23:104211. doi: 10.1016/j.exphem.2024.104211.
Int J Hematol
- NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
Correlation of ex vivo and in vivo ammonia production with L-asparaginase
biological activity in adults with lymphoid malignancies.
Int J Hematol. 2024;119:426-431.
- XU J, Zong S, Sheng T, Zheng J, et al
Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating
mTORC1 pathway-mediated apoptosis and autophagy.
Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
- USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in
Japanese patients with high-risk acute myeloid leukemia.
Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
J Biol Chem
- KANEFSKY J, Basse M, Sokei J, di Martino O, et al
DISRUPTION OF POLYUNSATURATED FATTY ACID BIOSYNTHESIS DRIVES STING-DEPENDENT
ACUTE MYELOID LEUKEMIA CELL MATURATION AND DEATH.
J Biol Chem. 2024 Mar 22:107214. doi: 10.1016/j.jbc.2024.107214.
J Clin Oncol
- RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin
With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With
Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3
Mutations.
J Clin Oncol. 2024;42:1158-1168.
J Natl Cancer Inst
- HANTEL A, Brunner AM, Plascak JJ, Uno H, et al
Race/ethnic associations with comprehensive cancer center access and clinical
trial enrollment for acute leukemia.
J Natl Cancer Inst. 2024 Mar 22:djae067. doi: 10.1093.
J Pediatr Hematol Oncol
- DEVINE KJ, Trivedi H, Reilly AF
B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution.
J Pediatr Hematol Oncol. 2024;46:e254-e258.
Leuk Lymphoma
- CORTES J, Jonas BA, Schiller G, Mims A, et al
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1
(mIDH1) acute myeloid leukemia (AML).
Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
- MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia:
a promising high sensitivity diagnostic approach.
Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
Leuk Res
- MUTHIAH C, Narra R, Atallah E, Juan W, et al
Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era
of novel therapies using the SEER registry.
Leuk Res. 2024;140:107496.
- SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or
dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Leuk Res. 2024;139:107481.
Leukemia
- BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
Management and outcome of patients with chronic myeloid leukemia in blast phase
in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast
Phase Registry.
Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
- DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus
hypomethylating agents versus conventional chemotherapy.
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
- KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1
tyrosine kinase inhibitors in chronic myeloid leukemia?
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.
- BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
Measurable residual disease quantification in adult patients with
KMT2A-rearranged acute lymphoblastic leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.
- FARROKHI A, Atre T, Rever J, Fidanza M, et al
The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic
leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
PLoS One
- SUN K, Tian X, Xia J, Li Q, et al
Promoting leisure functions through setting creative linguistic landscapes in
recreational zones.
PLoS One. 2024;19:e0299775.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016